Corrigendum: Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice by Monica Bartucci et al.
CORRECTION
published: 11 July 2016
doi: 10.3389/fcell.2016.00074
Frontiers in Cell and Developmental Biology | www.frontiersin.org 1 July 2016 | Volume 4 | Article 74
Edited and reviewed by:
Darius Widera,
University of Reading, UK
*Correspondence:
Hatem E. Sabaawy
sabaawhe@cinj.rutgers.edu
Specialty section:
This article was submitted to
Stem Cell Research,
a section of the journal
Frontiers in Cell and Developmental
Biology
Received: 24 June 2016
Accepted: 28 June 2016
Published: 11 July 2016
Citation:
Bartucci M, Ferrari AC, Kim IY,
Ploss A, Yarmush M and Sabaawy HE
(2016) Corrigendum: Personalized
Medicine Approaches in Prostate
Cancer Employing Patient Derived 3D
Organoids and Humanized Mice.
Front. Cell Dev. Biol. 4:74.
doi: 10.3389/fcell.2016.00074
Corrigendum: Personalized Medicine
Approaches in Prostate Cancer
Employing Patient Derived 3D
Organoids and Humanized Mice
Monica Bartucci 1, Anna C. Ferrari 1, Isaac Yi Kim 1, Alexander Ploss 1, 2, Martin Yarmush 3, 4
and Hatem E. Sabaawy 1, 5*
1 Rutgers Cancer Institute of New Jersey, Rutgers University, New Brunswick, NJ, USA, 2Department of Molecular Biology,
Princeton University, Princeton, NJ, USA, 3Center for Engineering in Medicine, Shriners Hospitals for Children and
Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 4Department of
Biomedical Engineering, Rutgers University, New Brunswick, NJ, USA, 5Department of Medicine, Rutgers Biomedical and
Health Sciences (RBHS)-Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA
Keywords: organoids, prostate cancer, precision medicine, precision therapeutics
A corrigendum on
Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D
Organoids and Humanized Mice
by Bartucci, M., Ferrari, A. C., Kim, I. Y., Ploss, A., Yarmush, M., and Sabaawy, H. E. (2016) Front.
Cell Dev. Biol. 4:64. doi: 10.3389/fcell.2016.00064
Reason for Corrigendum:
In the original Perspective article there was an error in the mouse strain described in Figure 2G its
legend, and the corresponding reference.
In the first paragraph of the section Reconstitution of Mice with a Humanized Immune System,
the reference (Chen et al., 2009) has been replaced with (Shultz et al., 2012).
The correct versions of Figure 2, its legend, and the first paragraph of the section Reconstitution
of Mice with a Humanized Immune System appear below. The authors sincerely apologize for the
error. This error does not change the scientific conclusions of the Perspective in any way.
The original article has been updated.
RECONSTITUTION OF MICE WITH A HUMANIZED IMMUNE
SYSTEM
Humanized mice are immunodeficient animals engrafted with human hematopoietic stem cells
(HSCs) that give rise to various lineages of human blood cells throughout the life of the mouse
(Drake et al., 2012). By simultaneously humanizing the immune system of recipient animals
and challenging them with implanted human tumor cells in prostate organoids, the interactions
between human immune cells and tumor cells can be interrogated (Chen and Mellman, 2013).
Mice engrafted with components of a human immune system (HIS) are routinely generated by
engrafting human HSCs isolated from human fetal liver (HFL), BM, or cord blood into highly
immunodeficient mouse strains, such as NOD Rag1−/− IL2Rαnull (NRG) mice, NOD SCID
IL2Rαnull (NSG) or Balb/C Rag2−/− IL2Rαnull (BRG), that support better human hematopoietic
cell engraftment (Figures 2D–F). We have pursued improved strategies to enhance the human
immune cell reconstitution and function in humanized mice (Billerbeck et al., 2014). A variety
of other strategies are also being pursued, including, but are not limited to: the expression of
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FIGURE 2 | PCa organoids to model tumor heterogeneity and develop immunotherapy in humanized mice. (A) H&E of RP section from a PCa patient
shown in 4x. (B) The outlined area in (A) is displayed in 200x, showing the outline of benign prostate gland (green), prostatic intraepithelial neoplasia (PIN) region
(yellow), and a three foci region of PCa (Blue). (C) Single-cell organoids reflect the heterogeneity in primary PCa. Immunofluorescence (IF) images show DAPI as
nuclear staining, PSA (center region), CK14 (in cells lacking PSA staining, i.e., transit amplifying cells). Multiple organoids derived from the same patient’s PCa
expressing PSA and CK14 (right), low and localized (top) and low/negative (bottom). (D) Human immune system (HIS) reconstitution in NRG HIS. Fraction of human
CD45+ cells of total CD45+ cells detected in the HSC transplanted NRG mice. (E) Indicated leukocyte subpopulations were determined by FACS analysis of PBMC
in NRG mice. (F) Indicated immune cell subpopulations in NRG and HIS-NRG mice are shown as dot plots.
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human orthologs of non-redundant cytokines with limited
biological cross-reactivity to foster the development of human
immune cell lineages which currently do not develop efficiently
in conventional humanized mice; expression of human MHC in
the absence of mouse MHC to ensure faithful presentation of
self- and virally-derived peptides to human T-cells and to reduce
graft-versus-host-disease; co-transplantation of HSC donor-
matched human thymic cortical epithelium to facilitate proper
T-cell selection; the improvement of lymphoid architectural
organization, especially in the spleen and lymph-nodes, to
allow for adequate T- and B-cell priming; genetic replacement
of non-compatible immune cell receptors and chemokines
expressed on non-hematopoietically derived cells to improve
immune functions such as immune cell trafficking; and the
introduction of a human microbiome to account for the effects
of species-specific commensals on the immune system (reviewed
in Shultz et al., 2012). We are now poised to reconstitute
mice with a HIS from PCa patients along with their prostate
organoids to examine the personalized immune responses against
PCa cells in the presence or absence of PCa therapy to
overcome resistance and provide new approaches for cancer
therapy.
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